Industry News

• Scientists discover causative genetic mutation associated with neurologic disorder  Scientists using advanced genomic analysis technologies from Life Technologies have sequenced an individual's genome and identified the specific causative mutation associated with Charcot-Marie-Tooth Disease (CMT).
  Life Technologies Corporation March 10, 2010  
• Monsanto ranks no. 28 on the 2010 DiversityInc Top 50 Companies for Diversity(R) list  Monsanto Company has been named to The 2010 DiversityInc Top 50 Companies for Diversity(R) list for its demonstrated use of measurable diversity best practices and results. A total of 449 companies participated this year, up 12 percent from last year.
  Monsanto Company March 10, 2010  
• Vermillion announces Scientific Advisory Board appointments  Vermillion announced the appointment of its distinguished Scientific Advisory Board to assist in directing the Company's product development strategies.
  Vermillion, Inc. March 10, 2010  
• Affymax(R) receives $5 million milestone payment on initiation of Phase 3 clinical trials  Affymax announced that it has received a $5 million development milestone payment from Takeda Pharmaceutical as part of the companies' exclusive global agreement to develop and commercialize Hematide(TM), Affymax's investigational drug for the treatment of anemia in chronic renal failure patients.
  Affymax, Inc. March 10, 2010  
• Medicis increases cash dividend to $0.06 per share  Medicis announced that its Board of Directors declared a quarter-end cash dividend of $0.06 per issued and outstanding share of its Common Stock payable on April 30, 2010, to stockholders of record at the close of business on April 1, 2010.
  Medicis March 10, 2010  
• Cytokinetics announces Orphan Drug Designation granted to CK-2017357  Cytokinetics announced that its fast skeletal muscle troponin activator, CK-2017357, has been granted orphan-drug designation by the U.S. Food and Drug Administration (FDA) for the potential treatment of amyotrophic lateral sclerosis (ALS), also commonly known as Lou Gehrig's Disease.
  Cytokinetics, Incorporated March 10, 2010  
• Abbott receives U.S. FDA approval for new cataract multifocal intraocular lens  Abbott announced it has received U.S. Food and Drug Administration (FDA) approval for the TECNIS(R) Multifocal 1-Piece intraocular lens (IOL) for cataract patients with and without presbyopia.
  Abbott March 10, 2010  
• FDA approves Botox to treat spasticity in flexor muscles of the elbow, wrist and fingers  The U.S. Food and Drug Administration approved Botox (onabotulinumtoxin A) to treat spasticity in the flexor muscles of the elbow, wrist, and fingers in adults. Spasticity is common after stroke, traumatic brain injury, or the progression of multiple sclerosis.
  FDA March 09, 2010  
• Bruker and Agilent Technologies announce agreement  Varian announced that Bruker Corporation and Agilent Technologies have entered into a definitive asset purchase agreement pursuant to which Bruker will acquire certain product lines of Varian.
  Varian, Inc. March 09, 2010  
• BOTOX(R) (OnabotulinumtoxinA) receives FDA approval for treatment of upper limb spasticity  Allergan announced that the United States Food and Drug Administration (FDA) has approved BOTOX(R) (onabotulinumtoxinA) for the treatment of increased muscle stiffness in the elbow, wrist and fingers in adults with upper limb spasticity.
  Allergan, Inc. March 09, 2010  

   (next 10 articles)